From chemical tools to clinical medicines: Nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds

Journal of Medicinal Chemistry

Volumn 57, Issue 17, 2014, Pages 7145-7159

  Sweeney, Zachary K ^a   Fu, Jiping ^a   Wiedmann, Brigitte ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; INTERFERON; RIBAVIRIN; SANGLIFEHRIN; UNCLASSIFIED DRUG; (MELLE-4)CYCLOSPORIN; ANTIVIRUS AGENT; CYCLOPHILIN; CYCLOSPORIN; ENZYME INHIBITOR; LACTONE; PROTEIN BINDING; SANGLIFEHRIN A; SCY-635; SPIRO COMPOUND;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CLINICAL TRIAL; ENZYME ACTIVITY; HEPATITIS C; HUMAN; IN VITRO STUDY; NONHUMAN; REPERFUSION INJURY; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HEPACIVIRUS; HOST PATHOGEN INTERACTION; MEDICINAL CHEMISTRY; METABOLISM; PHYSIOLOGY; PROCEDURES; PROTEIN TERTIARY STRUCTURE; TRENDS; VIROLOGY;

ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CYCLOPHILINS; CYCLOSPORINE; CYCLOSPORINS; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; LACTONES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907164366     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500223x     Document Type: Article

References (145)

1. Davis, T. L.; Walker, J. R.; Campagna-Slater, V.; Finerty, P. J.; Paramanathan, R.; Bernstein, G.; MacKenzie, F.; Tempel, W.; Ouyang, H.; Lee, W. H.; Eisenmesser, E. Z.; Dhe-Paganon, S. Structural and Biochemical Characterization of the Human Cyclophilin Family of Peptidyl-Prolyl Isomerases PLoS Biol. 2010, 8, e1000439
2. Borel, J. F.; Di Padova, F.; Mason, J.; Quesniaux, V.; Ryffel, B.; Wenger, R. Pharmacology of Cyclosporine Pharmacol. Rev. 1989, 41, 239-242
3. Sanglier, J. J.; Quesniaux, V.; Hofmann, H.; Mahnke, M.; Memmert, K.; Schuler, W.; Zenke, G.; Gschwind, L.; Maurer, C.; Schilling, W. Sanglifehrins A, B, C and D, Novel Cyclophilin-Binding Compounds Isolated from Streptomyces sp. A92-308110. I. Taxonomy, Fermentation, Isolation and Biological Activity J. Antibiot. 1999, 52, 466-473
4. Peel, M.; Scribner, A. Optimization of Cyclophilin Inhibitors for Use in Antiviral Therapy. In Successful Strategies for the Discovery of Antiviral Drugs; Desai, M. C.; Meanwell, N. A., Eds.; RSC Drug Discovery Series, Vol. 32; Royal Society of Chemistry: Cambridge, U.K., 2013; pp 384-418.
5. Baugh, J.; Gallay, P. Cyclophilin Involvement in the Replication of Hepatitis C Virus and Other Viruses Biol. Chem. 2012, 393, 579-587
6. Frausto, S. D.; Lee, E.; Tang, H. Cyclophilins as Modulators of Viral Replication Viruses 2013, 5, 1684-1701
7. Yurchenko, V.; Constant, S.; Eisenmesser, E.; Bukrinsky, M. Cyclophilin-CD147 Interactions: A New Target for Anti-Inflammatory Therapeutics Clin. Exp. Immunol. 2010, 160, 305-317
8. Gill, R. S.; Bigam, D. L.; Cheung, P.-Y. The Role of Cyclosporine in the Treatment of Myocardial Reperfusion Injury Shock 2012, 37, 341-347
9. Lee, J.; Kim, S. S. Current Implications of Cyclophilins in Human Cancers J. Exp. Clin. Cancer Res. 2010, 29, 97
10. Ito, K.; Passioura, T.; Suga, H. Technologies for the Synthesis of mRNA-Encoding Libraries and Discovery of Bioactive Natural Product-Inspired Non-Traditional Macrocyclic Peptides Molecules 2013, 18, 3502-3528
11. Schärfer, C.; Schulz-Gasch, T.; Ehrlich, H.-C.; Guba, W.; Rarey, M.; Stahl, M. Torsion Angle Preferences in Druglike Chemical Space: A Comprehensive Guide J. Med. Chem. 2013, 56, 2016-2028
12. Bockus, A. T.; McEwen, C. M.; Lokey, R. S. Form and Function in Cyclic Peptide Natural Products: A Pharmacokinetic Perspective Curr. Top. Med. Chem. 2013, 13, 821-836
13. Alex, A.; Millan, D. S.; Perez, M.; Wakenhut, F.; Whitlock, G. A. Intramolecular Hydrogen Bonding To Improve Membrane Permeability and Absorption in beyond Rule of Five Chemical Space MedChemComm 2011, 2, 669
14. Heusler, K.; Pletscher, A. The Controversial Early History of Cyclosporin Swiss Med. Wkly. 2001, 131, 299-302
15. Columbani, P. M.; Ross, A.; Hess, A. D. Cyclosporin A Binding to Calmodulin: A Possible Site of Action on T Lymphocytes Science 1985, 228, 337-339
16. Schreiber, S. L. Immunophilin Sensitive Protein Phosphatase Action in Cell Signaling Pathways Minireview Cell 1992, 70, 365-368
17. Schreiber, S. L.; Crabtree, G. R. The Mechanism of Action of Cyclosporin A and FK506 Immunol. Today 1992, 13, 136-142
18. Peel, M.; Scribner, A. Cyclophilin Inhibitors as Antiviral Agents Bioorg. Med. Chem. Lett. 2013, 23, 4485-4492
19. Fischer, G.; Bang, H.; Mech, C. Determination of Enzymatic Catalysis for the Cis-Trans-Isomerization of Peptide Binding in Proline-Containing Peptides Biomed. Biochim. Acta 1984, 43, 1101-1111
20. Handschumacher, R.; Harding, M.; Rice, J. Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin A Science 1984, 226, 5-8
21. Harding, M. W.; Handschumacher, R. E.; Speicher, D. W. Isolation and Amino Acid Sequence of Cyclophilin J. Biol. Chem. 1986, 261, 8547-8555
22. Fischer, G.; Wittmann-Liebold, B.; Lang, K.; Kiefhaber, T.; Schmid, F. X. Cyclophilin and Peptidyl-Prolyl Cis-Trans Isomerase Are Probably Identical Proteins Nature 1989, 337, 476-478
23. Takahashi, N.; Hayano, T.; Suzuki, M. Peptidyl-Prolyl Cis-Trans Isomerase Is the Cyclosporin A-Binding Protein Cyclophilin Nature 1989, 337, 473-475
24. Galat, A. Function-Dependent Clustering of Orthologues and Paralogues of Cyclophilins Proteins 2004, 56, 808-820
25. Galat, A.; Bua, J. Molecular Aspects of Cyclophilins Mediating Therapeutic Actions of Their Ligands Cell. Mol. Life Sci. 2010, 67, 3467-3488
26. Mouse Genome Informatics. The Jackson Laboratory. http://www.informatics.jax.org (accessed Jan 8, 2014).
27. Choi, J. W.; Sutor, S. L.; Lindquist, L.; Evans, G. L.; Madden, B. J.; Bergen, H. R.; Hefferan, T. E.; Yaszemski, M. J.; Bram, R. J. Severe Osteogenesis Imperfecta in Cyclophilin B-Deficient Mice PLoS Genet. 2009, 5, e1000750
28. Zhang, J.; Herscovitz, H. Nascent Lipidated Apolipoprotein B Is Transported to the Golgi as an Incompletely Folded Intermediate As Probed by Its Association with Network of Endoplasmic Reticulum Molecular Chaperones, GRP94, ERp72, BiP, Calreticulin, and Cyclophilin B J. Biol. Chem. 2003, 278, 7459-7468
29. Fang, F.; Zheng, J.; Galbaugh, T. L.; Fiorillo, A. A.; Hjort, E. E.; Zeng, X.; Clevenger, C. V. Cyclophilin B as a Co-Regulator of Prolactin-Induced Gene Expression and Function in Breast Cancer Cells J. Mol. Endocrinol. 2010, 44, 319-329
30. Pushkarsky, T.; Yurchenko, V.; Vanpouille, C.; Brichacek, B.; Vaisman, I.; Hatakeyama, S.; Nakayama, K. I.; Sherry, B.; Bukrinsky, M. I. Cell Surface Expression of CD147/EMMPRIN Is Regulated by Cyclophilin 60 J. Biol. Chem. 2005, 280, 27866-27871
31. Heine, S. J.; Olive, D.; Gao, J.-L.; Murphy, P. M.; Bukrinsky, M. I.; Constant, S. L. Cyclophilin A Cooperates with MIP-2 To Augment Neutrophil Migration J. Inflammation Res. 2011, 4, 93-104
32. Wang, W. L.; Yuan, Y. J.; Xue, F. S.; Liao, X.; Wang, Q.; Xiong, J.; Liu, J. H. Extracellular Cyclophilin A May Be a Potential Target To Protect against Myocardial Reperfusion Injury Med. Hypotheses 2011, 77, 734-738
33. Stemmy, E. J.; Balsley, M. A; Jurjus, R. A.; Damsker, J. M.; Bukrinsky, M. I.; Constant, S. L. Blocking Cyclophilins in the Chronic Phase of Asthma Reduces the Persistence of Leukocytes and Disease Reactivation Am. J. Respir. Cell Mol. Biol. 2011, 45, 991-998
34. Rehman, H.; Sun, J.; Shi, Y.; Ramshesh, V. K.; Liu, Q.; Currin, R. T.; Lemasters, J. J.; Zhong, Z. NIM811 Prevents Mitochondrial Dysfunction, Attenuates Liver Injury, and Stimulates Liver Regeneration after Massive Hepatectomy Transplantation 2011, 91, 406-412
35. Mbye, L. H.; Singh, I. N.; Sullivan, P. G.; Springer, J. E.; Hall, E. D. Attenuation of Acute Mitochondrial Dysfunction after Traumatic Brain Injury in Mice by NIM811, a Non-Immunosuppressive Cyclosporin A Analog Exp. Neurol. 2008, 209, 243-253
36. Readnower, R. D.; Pandya, J. D.; McEwen, M. L.; Pauly, J. R.; Springer, J. E.; Sullivan, P. G. Post-Injury Administration of the Mitochondrial Permeability Transition Pore Inhibitor, NIM811, Is Neuroprotective and Improves Cognition after Traumatic Brain Injury in Rats J. Neurotrauma 2011, 28, 1845-1853
37. Korde, A. S.; Pettigrew, L. C.; Craddock, S. D.; Pocernich, C. B.; Waldmeier, P. C.; Maragos, W. F. Protective Effects of NIM811 in Transient Focal Cerebral Ischemia Suggest Involvement of the Mitochondrial Permeability Transition J. Neurotrauma 2007, 24, 895-908
38. Zhong, Z.; Theruvath, T. P.; Currin, R. T.; Waldmeier, P. C.; Lemasters, J. J. NIM811, a Mitochondrial Permeability Transition Inhibitor, Prevents Mitochondrial Depolarization in Small-for-Size Rat Liver Grafts Am. J. Transplant. 2007, 7, 1103-1111
39. Rasola, A.; Bernardi, P. The Mitochondrial Permeability Transition Pore and Its Involvement in Cell Death and in Disease Pathogenesis Apoptosis 2007, 12, 815-833
40. Elrod, J. W.; Molkentin, J. D. Physiologic Functions of Cyclophilin D and the Mitochondrial Permeability Transition Pore Circ. J. 2013, 77, 1111-1122
41. NeuroVive. www.neurovive.com.
42. Chatterji, U.; Bobardt, M. D.; Stanfield, R.; Ptak, R. G.; Pallansch, L. A.; Ward, P. A.; Jones, M. J.; Stoddart, C. A.; Scalfaro, P.; Dumont, J.-M.; Besseghir, K.; Rosenwirth, B.; Gallay, P. A. Naturally Occurring Capsid Substitutions Render HIV-1 Cyclophilin A Independent in Human Cells and TRIM-Cyclophilin-Resistant in Owl Monkey Cells J. Biol. Chem. 2005, 280, 40293-40300
43. Hopkins, S.; Gallay, P. Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C Infection Viruses 2012, 4, 2558-2577
44. Gallay, P. A.; Lin, K. Profile of Alisporivir and Its Potential in the Treatment of Hepatitis C Drug Des. Dev. Ther. 2013, 7, 105-115
45. Gaither, L. A.; Borawski, J.; Anderson, L. J.; Balabanis, K. A.; Devay, P.; Joberty, G.; Rau, C.; Schirle, M.; Bouwmeester, T.; Mickanin, C.; Zhao, S.; Vickers, C.; Lee, L.; Deng, G.; Baryza, J.; Fujimoto, R. A.; Lin, K.; Compton, T.; Wiedmann, B. Multiple Cyclophilins Involved in Different Cellular Pathways Mediate HCV Replication Virology 2010, 397, 43-55
46. Hopkins, S.; DiMassimo, B.; Rusnak, P.; Heuman, D.; Lalezari, J.; Sluder, A.; Scorneaux, B.; Mosier, S.; Kowalczyk, P.; Ribeill, Y.; Baugh, J.; Gallay, P. The Cyclophilin Inhibitor SCY-635 Suppresses Viral Replication and Induces Endogenous Interferons in Patients with Chronic HCV Genotype 1 Infection J. Hepatol. 2012, 57, 47-54
47. Garcia-Rivera, J. A.; Bobardt, M.; Chatterji, U.; Hopkins, S.; Gregory, M. A.; Wilkinson, B.; Lin, K.; Gallay, P. A. Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to Alisporivir Antimicrob. Agents Chemother. 2012, 56, 5113-5121
48. Zeisel, M. B.; Lupberger, J.; Fofana, I.; Baumert, T. F. Host-Targeting Agents for Prevention and Treatment of Chronic Hepatitis C-Perspectives and Challenges J. Hepatol. 2013, 58, 375-384
49. Wenger, R. M.; France, J.; Bovermann, G.; Walliser, L.; Widmer, a; Widmer, H. The 3D Structure of a Cyclosporin Analogue in Water Is Nearly Identical to the Cyclophilin-Bound Cyclosporin Conformation FEBS Lett. 1994, 340, 255-259
50. Taylor, P.; Husi, H.; Kontopidis, G.; Walkinshaw, M. D. Structures of Cyclophilin-Ligand Complexes Prog. Biophys. Mol. Biol. 1997, 67, 155-181
51. Rosen, M. K.; Belshaw, P. J.; Alberg, D. G.; Schreiber, S. L. The Conformation of Cyclosporin a Bound to Cyclophilin Is Altered (Once Again) following Binding to Calcineurin: An Analysis of Receptor-Ligand-Receptor Interactions Bioorg. Med. Chem. Lett. 1992, 2, 747-753
52. O'Donohue, M. F.; Burgess, a W.; Walkinshaw, M. D.; Treutlein, H. R. Modeling Conformational Changes in Cyclosporin A Protein Sci. 1995, 4, 2191-2202
53. Mikol, V.; Kallen, J.; Pflügl, G.; Walkinshaw, M. D. X-ray Structure of a Monomeric Cyclophilin A-Cyclosporin A Crystal Complex at 2.1 Å Resolution J. Mol. Biol. 1993, 234, 1119-1130
54. Jin, L.; Harrison, S. C. Crystal Structure of Human Calcineurin Complexed with Cyclosporin A and Human Cyclophilin Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13522-13526
55. Akhlaghi, F.; Trull, A. K. Distribution of Cyclosporin in Organ Transplant Recipients Clin. Pharmacokinet. 2002, 41, 615-637
56. Awni, W. M.; Sawchuk, R. J. The Pharmacokinetics of Cyclosporine II. Blood Plasma Distribution and Binding Studies Drug Metab. Dispos. 1985, 13, 133-138
57. Amundsen, R.; Christensen, H.; Zabihyan, B.; Åsberg, A. Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin Drug Metab. Dispos. 2010, 38, 1499-1504
58. Shitara, Y.; Nagamatsu, Y.; Wada, S.; Sugiyama, Y.; Horie, T. Long-Lasting Inhibition of the Transporter-Mediated Hepatic Uptake of Sulfobromophthalein by Cyclosporin A in Rats Drug Metab. Dispos. 2009, 37, 1172-1178
59. Ogimura, E.; Sekine, S.; Horie, T. Bile Salt Export Pump Inhibitors Are Associated with Bile Acid-Dependent Drug-Induced Toxicity in Sandwich-Cultured Hepatocytes Biochem. Biophys. Res. Commun. 2011, 416, 313-317
60. El-Sheikh, A. A. K.; Greupink, R.; Wortelboer, H. M.; van den Heuvel, J. J. M. W.; Schreurs, M.; Koenderink, J. B.; Masereeuw, R.; Russel, F. G. M. Interaction of Immunosuppressive Drugs with Human Organic Anion Transporter (OAT) 1 and OAT3, and Multidrug Resistance-Associated Protein (MRP) 2 and MRP4 Transl. Res. 2013, 162, 398-409
61. Loor, F.; Tiberghien, F.; Wenandy, T.; Didier, A.; Traber, R. Cyclosporins: Structure-Activity Relationships for the Inhibition of the Human J. Med. Chem. 2002, 45, 4598-4612
62. Kolitz, J. E.; George, S. L.; Marcucci, G.; Vij, R.; Powell, B. L.; Allen, S. L.; DeAngelo, D. J.; Shea, T. C.; Stock, W.; Baer, M. R.; Hars, V.; Maharry, K.; Hoke, E.; Vardiman, J. W.; Bloomfield, C. D.; Larson, R. A. P-Glycoprotein Inhibition Using Valspodar (PSC-833) Does Not Improve Outcomes for Patients Younger Than Age 60 Years with Newly Diagnosed Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19808 Blood 2010, 116, 1413-1421
63. Friedenberg, W. R.; Rue, M.; Blood, E. A.; Dalton, W. S.; Shustik, C.; Larson, R. A.; Sonneveld, P.; Greipp, P. R. Phase III Study of PSC-833 (Valspodar) in Combination with Vincristine, Doxorubicin, and Dexamethasone (Valspodar/VAD) versus VAD Alone in Patients with Recurring or Refractory Multiple Myeloma (E1A95): A Trial of the Eastern Cooperative Oncology Group Cancer 2006, 106, 830-838
64. Kovacs, S. J.; Ke, J.; Dabovic, K.; Barve, A.; Stein, D. S. Therapeutic Dose Effects of the Cyclophilin Inhibitor Alisporivir (ALV) on Circulating Bilirubin Concentrations in Healthy Subjects Dig. Dis. Week 2012, Abstract 1081
65. Giacomini, K. M.; Huang, S.-M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L. R.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane Transporters in Drug Development Nat. Rev. Drug Discovery 2010, 9, 215-236
66. Karlgren, M.; Ahlin, G.; Bergström, C. A.; Svensson, R.; Palm, J.; Artursson, P. In Vitro and in Silico Strategies To Identify OATP1B1 Inhibitors and Predict Clinical Drug-Drug Interactions Pharm. Res. 2012, 29, 411-426
67. Wenger, R. M. Synthesis of Cyclosporine. Total Syntheses of Cyclosporin A and Cyclosporin H, Two Fungal Metabolites Isolated from the Species Tolypocadium Inflatum Gams Helv. Chim. Acta 1984, 67, 502-525
68. Wenger, R. Synthesis of Cyclosporin and Its Analogs: Relation between Structure and Immunosuppressive Activity Angew. Chem., Int. Ed. Engl. 1985, 24, 77-138
69. Wenger, R. M.; Payne, T. G.; Schreier, M. H. Cyclosporine: Chemistry, Structure-Activity Relationships and Mode of Action Prog. Clin. Biochem. Med. 1986, 3, 157-191
70. Seebach, D.; Bossler, H.; Gruendler, H.; Shoda, S.; Wenger, R. C-Alkylation of Peptides through Polylithiated and Lithium Chloride Solvated Derivatives Containing Sarcosine Lithium Enolate Units Helv. Chim. Acta 1991, 74, 197-224
71. Ko, S. Y.; Wenger, R. M. 53. Solid-Phase Total Synthesis of Cyclosporine Analogues Helv. Chim. Acta 1997, 80, 695-705
72. Traber, R.; Hofmann, H.; Loosli, H.-R.; Ponelle, M.; von Wartburg, A. Neue Cyclosporine aus Tolypocladium Inflatum die Cyclosporine K-Z Helv. Chim. Acta 1987, 70, 13-36
73. Quesniaux, V. F.; Schreier, M. H.; Wenger, R. M.; Hiestand, P. C.; Harding, M. W.; Van Regenmortel, M. H. Cyclophilin Binds to the Region of Cyclosporine Involved in Its Immunosuppressive Activity Eur. J. Immunol. 1987, 17, 1359-1365
74. Sigal, N. H.; Dumont, F.; Durette, P.; Siekierka, J. J.; Peterson, L.; Rich, D. H.; Dunlap, B. E.; Staruch, M. J.; Melino, M. R.; Koprak, S. L. Is Cyclophilin Involved in the Immunosuppressive and Nephrotoxic Mechanism of Action of Cyclosporin A? J. Exp. Med. 1991, 173, 619-628
75. Liu, J.; Albers, M. W.; Wandless, T. J.; Luan, S.; Alberg, D. G.; Belshaw, P. J.; Cohen, P.; MacKintosh, C.; Klee, C. B.; Schreiber, S. L. Inhibition of T Cell Signaling by Immunophilin-Ligand Complexes Correlates with Loss of Calcineurin Phosphatase Activity Biochemistry 1992, 31, 3896-3901
76. Papageorgiou, C.; Borer, X.; French, R. R. Calcineurin Has a Very Tight-Binding Pocket for the Side Chain of Residue 4 of Cyclosporin Bioorg. Med. Chem. Lett. 1994, 4, 267-272
77. Thériault, Y.; Logan, T. M.; Meadows, R.; Yu, L.; Olejniczak, E. T.; Holzman, T. F.; Simmer, R. L.; Fesik, S. W. Solution Structure of the Cyclosporin A/Cyclophilin Complex by NMR Nature 1993, 361, 88-91
78. Pflügl, G.; Kallen, J.; Schirmer, T.; Jansonius, J. N.; Zurini, M. G.; Walkinshaw, M. D. X-ray Structure of a Decameric Cyclophilin-Cyclosporin Crystal Complex Nature 1993, 361, 91-94
79. Zeder-Lutz, G.; Van Regenmortel, M. H.; Wenger, R.; Altschuh, D. Interaction of Cyclosporin A and Two Cyclosporin Analogs with Cyclophilin: Relationship between Structure and Binding J. Chromatogr., B: Biomed. Appl. 1994, 662, 301-306
80. Papageorgiou, C.; Florineth, A.; Mikol, V. Improved Binding Affinity for Cyclophilin A by a Cyclosporin Derivative Singly Modified at Its Effector Domain J. Med. Chem. 1994, 37, 3674-3676
81. Papageorgiou, C.; Sanglier, J.; Traber, R. Anti HIV-1 Activity of a Hydrophilic Cyclosporin Derivative with Improved Binding Affinity to Cyclophilin A Bioorg. Med. Chem. Lett. 1996, 6, 23-26
82. Billich, A.; Hammerschmid, F.; Peichl, P.; Wenger, R.; Zenke, G.; Billich, A.; Hammerschmid, F.; Peichl, P.; Wenger, R.; Zenke, G.; Quesniaux, V.; Rosenwirth, B. Mode of Action of SDZ NIM 811, a Nonimmunosuppressive Cyclosporin A Analog with Activity against Human Immunodeficiency Virus J. Virol. 1995, 69, 2451-2461
83. Malesevic, M.; Gutknecht, D.; Prell, E.; Klein, C.; Schumann, M.; Nowak, R. A.; Simon, J. C.; Schiene-Fischer, C.; Saalbach, A. Anti-Inflammatory Effects of Extracellular Cyclosporins Are Exclusively Mediated by CD147 J. Med. Chem. 2013, 56, 7302-7311
84. Lin, K. Discovery of Cyclophilin Inhibitor NIM811 as a Novel Threapeutic Agent for HCV. In Antiviral Drugs: From Basic Discovery Through Clinical Trials; Kazmierski, W. M., Ed.; Wiley: Hoboken, NJ, 2011; pp 317-329.
85. Teraoka, S.; Mishiro, S.; Ebihara, K.; Sanaka, T.; Yamaguchi, Y.; Nakajima, I.; Kawai, T.; Yagisawa, T.; Honda, H.; Fuchinoue, S.; Kakahashi, K.; Toma, H.; Agishi, T.; Ota, K. Effect of Cyclosporine on Proliferation of Non-A, Non-B Hepatitis Virus Transplant. Proc. 1988, 20, 868-876
86. Goto, K.; Watashi, K.; Murata, T.; Hishiki, T.; Hijikata, M.; Shimotohno, K. Evaluation of the Anti-Hepatitis C Virus Effects of Cyclophilin Inhibitors, Cyclosporin A, and NIM811 Biochem. Biophys. Res. Commun. 2006, 343, 879-884
87. Puyang, X.; Poulin, D. L.; Mathy, J. E.; Anderson, L. J.; Ma, S.; Fang, Z.; Zhu, S.; Lin, K.; Fujimoto, R.; Compton, T.; Wiedmann, B. Mechanism of Resistance of Hepatitis C Virus Replicons to Structurally Distinct Cyclophilin Inhibitors Antimicrob. Agents Chemother. 2010, 54, 1981-1987
88. Lawitz, E.; Godofsky, E.; Rouzier, R.; Marbury, T.; Nguyen, T.; Ke, J.; Huang, M.; Praestgaard, J.; Serra, D.; Evans, T. G. Safety, Pharmacokinetics, and Antiviral Activity of the Cyclophilin Inhibitor NIM811 Alone or in Combination with Pegylated Interferon in HCV-Infected Patients Receiving 14 Days of Therapy Antiviral Res. 2011, 89, 238-245
89. Wang, H.; Zhang, Y.; Wang, T.; You, H.; Jia, J. N -Methyl-4-Isoleucine Cyclosporine Attenuates CCl-Induced Liver Fibrosis in Rats by Interacting with Cyclophilin B and D J. Gastroenterol. Hepatol. 2011, 26, 558-567
90. Rehman, H.; Ramshesh, V. K.; Theruvath, T. P.; Kim, I.; Currin, R. T.; Giri, S.; Lemasters, J. J.; Zhong, Z. NIM811 (N -Methyl-4-Isoleucine Cyclosporine), a Mitochondrial Permeability Transition Inhibitor, Attenuates Cholestatic Liver Injury but Not Fibrosis in Mice J. Pharmacol. Exp. Ther. 2008, 327, 699-706
91. Waldmeier, P. C.; Feldtrauer, J.-J.; Qian, T.; Lemasters, J. J. Inhibition of the Mitochondrial Permeability Transition by the Nonimmunosuppressive Cyclosporin Derivative NIM811 Mol. Pharmacol. 2002, 62, 22-29
92. Hokari, M.; Kuroda, S.; Iwasaki, Y. Pretreatment with the Ciclosporin Derivative NIM811 Reduces Delayed Neuronal Death in the Hippocampus after Transient Forebrain Ischaemia J. Pharm. Pharmacol. 2010, 62, 485-490
93. Korde, A. S.; Pettigrew, L. C.; Craddock, S. D.; Pocernich, C. B.; Waldmeier, P. C.; Maragos, W. F. Protective Effects of NIM811 in Transient Focal Cerebral Ischemia Suggest Involvement of the Mitochondrial Permeability Transition J. Neurotrauma 2007, 24, 895-908
94. Yurchenko, V.; Constant, S.; Bukrinsky, M. Dealing with the Family: CD147 Interactions with Cyclophilins Immunology 2006, 117, 301-309
95. Hubler, F.; Ru, T.; Patiny, L.; Muamba, T.; Guichou, Ë.; Mutter, M.; Wenger, R. Synthetic Routes to NEtXaa4-Cyclosporin A Derivatives as Potential Anti-HIV I Drugs Tetrahedron Lett. 2000, 41, 7193-7196
96. Wenger, R. M.; Mutter, M.; Ruckle, T. Novel Cyclosporin with Improved Activity Profile. WO 00/01715, 2000.
97. Radeke, H. H.; Christians, U.; Sewing, K.-F.; Resch, K. The Syntergistic Immunosuppressive Potential of Cyclosporin Metabolite Combinations Int. J. Immunopharmacol. 1992, 14, 595-604
98. Paeshuyse, J.; Kaul, A.; De Clercq, E.; Rosenwirth, B.; Dumont, J.-M.; Scalfaro, P.; Bartenschlager, R.; Neyts, J. The Non-Immunosuppressive Cyclosporin DEBIO-025 Is a Potent Inhibitor of Hepatitis C Virus Replication in Vitro Hepatology 2006, 43, 761-770
99. Coelmont, L.; Hanoulle, X.; Chatterji, U.; Berger, C.; Snoeck, J.; Bobardt, M.; Lim, P.; Vliegen, I.; Paeshuyse, J.; Vuagniaux, G.; Vandamme, A.-M.; Bartenschlager, R.; Gallay, P.; Lippens, G.; Neyts, J. DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A PLoS One 2010, 5, e13687
100. Nicolas, V. PK-PD Modelling and Simulation from a Biotech Company Perspective. Presented at PKUK 2010, Bristol, U.K., 2010.
101. Flisiak, R.; Jaroszewicz, J.; Flisiak, I.; Apiński, T. Update on Alisporivir in Treatment of Viral Hepatitis C Expert Opin. Invest. Drugs 2012, 21, 375-382
102. Wissing, E. R.; Millay, D. P.; Vuagniaux, G.; Molkentin, J. D. Debio-025 Is More Effective Than Prednisone in Reducing Muscular Pathology in Mdx Mice Neuromuscul. Disord. 2010, 20, 753-760
103. Evers, M.; Barrière, J.-C.; Bashiardes, G.; Bousseau, A.; Carry, J.-C.; Dereu, N.; Filoche, B.; Henin, Y.; Sablé, S.; Vuilhorgne, M.; Mignani, S. Synthesis of Non-Immunosuppressive Cyclophilin-Binding Cyclosporin A Derivatives as Potential Anti-HIV-1 Drugs Bioorg. Med. Chem. Lett. 2003, 13, 4415-4419
104. Seebach, D.; Beck, A. K.; Bossler, H. G.; Gerber, C.; Ko, S. Y.; Murtiashaw, C. W.; Naef, R.; Shoda, S.-I.; Thaler, A.; Krieger, M.; Wenger, R. Modification of Cyclosporin A (CS): Generation of an Enolate at the Sarcosine Residue and Reactions with Electrophiles Helv. Chim. Acta 1993, 76, 1564-1590
105. Hopkins, S.; Scorneaux, B.; Huang, Z.; Murray, M. G.; Wring, S.; Smitley, C.; Harris, R.; Erdmann, F.; Fischer, G.; Ribeill, Y. SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication in Vitro Antimicrob. Agents Chemother. 2010, 54, 660-672
106. Wring, S.; Wille, K.; Rewerts, C.; Randolph, R.; Scribner, A.; Hopkins, S. In Vitro Models for Assessing the Relative Risk of Hyperbilirubinemia Associated with Cyclophilin Inhibitor Therapy. Presented at the European Association for the Study of the Liver Meeting, 2010; Abstract 676.
107. Bobardt, M.; Hopkins, S.; Baugh, J.; Chatterji, U.; Hernandez, F.; Hiscott, J.; Sluder, A.; Lin, K.; Gallay, P. A. HCV NS5A and IRF9 Compete for CypA Binding J. Hepatol. 2012, 58, 16-23
108. Hopkins, S.; Gallay, P. Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C Infection Viruses 2012, 4, 2558-2577
109. Owens, C. M.; Brasher, B. B.; Polemeropoulos, A.; Long, J.; Gao, X.; Qiu, Y.; Wang, G.; Jiang, L.; Or, Y. S. EP-CyP546 Is a Potent Non-Immunosuppressive Cyclophilin Inhibitor with an Excellent Preclinical Profile. Presented at the Annual Meeting of AASLD, San Francisco, CA, 2011; Abstract 367.
110. Owens, C. M.; Rhodin, M. H.; Polemeropolous, A.; Long, J.; Wang, G.; Jiang, L.; Or, Y. S. Cyclophilin Inhibitor EDP-546 Is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to Its High Barrier to HCV Resistance. Presented at the Annual Meeting of the European Association for the Study of the Liver, Amsterdam, 2013; Abstract 1213.
111. Jiang, L.; Liu, S.; Phan, T.; Polemeropoulos, A. J.; Rhodin, M.; Owens, C. M.; Luo, X.; Hoang, K.; Long, J.; Gao, X.; Wang, G.; Or, Y. S. EDP-546, a Potent and Novel Cyclophilin Inhibitor with Favorable Preclinical Pharmacokinetic and Safety Profiles. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, 2012; Abstract 1895.
112. Su, Z.; Long, Z.; Huang, Z.; Yang, S. Novel Cyclosporin Derivatives for the Treatment and Prevention of Viral Infections. WO 2013/028615, 2013.
113. Su, Z.; Long, Z.; Huang, Z.; Yang, S. Novel Cyclosporin Derivatives for the Treatment of a Viral Infection. WO 2012/021796, 2012.
114. Su, Z.; Long, Z.; Huang, Z.; Yang, S. Novel Cyclosporin Derivatives for the Treatment and Prevention of a Viral Infection. WO 2012/075494, 2012.
115. Su, Z.; Huang, Z.; Long, Z.; Yang, S. Novel Cyclosporin Derivatives for the Treatment and Prevention of a Viral Infection. WO 2012/009715, 2012.
116. Carling, W. R.; Scowen, D. A.; Garst, M. E.; Stern, M. E.; Schaumburg, C. S. Cyclosporin Analogs. WO 2012/051193, 2012.
117. Búa, J.; Ruiz, A. M.; Potenza, M.; Fichera, L. E. In Vitro Anti-Parasitic Activity of Cyclosporin A Analogs on Trypanosoma cruzi Bioorg. Med. Chem. Lett. 2004, 14, 4633-4637
118. Hegmans, A.; Fenske, B. W.; Trepanier, D. J.; Abel, M. D.; Sugiyama, S.; Ure, D. R. Cyclosporine Analogue Molecules Modified at Amino Acid 1 and 3. WO 2012/079172, 2012.
119. Li, K.; Peel, M. R. Novel Cyclic Peptides. WO 2011/070364, 2011.
120. Papageorgiou, C.; Kallen, J.; France, J.; French, R. Conformational Control of Cyclosporin through Substitution of the N-5 Position. A New Class of Cyclosporin Antagonists Bioorg. Med. Chem. 1997, 5, 187-192
121. Eberle, M. K.; Hiestand, P.; Jutzi-Eme, A. M.; Nuninger, F.; Zihlmann, H. R. Preparation and in Vitro Activities of Ethers of [ d -Serine]8-cyclosporin J. Med. Chem. 1995, 38, 1853-1864
122. Scribner, A.; Houck, D.; Huang, Z.; Mosier, S.; Peel, M.; Scorneaux, B. Synthesis and Biological Evaluation of [ d -Lysine]8cyclosporin A Analogs as Potential Anti-HCV Agents Bioorg. Med. Chem. Lett. 2010, 20, 6542-6546
123. Lawen, A.; Traber, R.; Geyl, D. In Vitro Biosynthesis of [Thr2,Leu5,D-Hiv8,Leu10]-Cyclosporin, a Cyclosporin-Related Peptolide, with Immunosuppressive Activity by a Multienzyme Polypeptide J. Biol. Chem. 1991, 266, 15567-15570
124. Mikol, V.; Taylor, P.; Kallen, J.; Walkinshaw, M. D. Conformational Differences of an Immunosuppressant Peptolide in a Single Crystal and in a Crystal Complex with Human Cyclophilin A J. Mol. Biol. 1998, 283, 451-461
125. Wenger, R. M.; Mutter, M.; Garrouste, P.; Lysex, R.; Turpin, O.; Vuagniaux, G.; Nicolas, V.; Zanolari, L. N.; Crabbe, R. Cycloundecadepsipeptide Compounds and Use of Said Compounds as a Medicament. US 2011/212057, 2011.
126. Vuagniaux, G.; Gavillet, B.; Crabbe, R. Use of Cycloundecadepsipeptide Compounds. WO 2011/141891, 2011.
127. Sawada, M.; Tsujii, E.; Morishita, Y.; Uchida, M.; Katsumata, K.; Maki, K.; Nagata, M.; Makino, T.; Yoshimura, S.; Yamanaka, T.; Lund, G.; Kneteman, N. M.; Tyrrell, D. J. L. Preclinical Evaluation of ASP5286, a Novel Cyclophilin Inhibitor with Potent Anti-HCV Activity. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012; Abstract 1899.
128. Sakamoto, K.; Tsujii, E.; Miyauchi, M.; Nakanishi, T.; Yamashita, M.; Shigematsu, N.; Tada, T.; Izumi, S.; Okuhara, M. FR901459, a Novel Immunosuppressant Isolated from Stachybotrys Chartarum No. 19392 J. Antibiot. (Tokyo) 1993, 46, 1788-1798
129. Neya, M.; Yoshimura, S.; Kamijyo, K.; Makino, T.; Yasuda, M.; Yamanaka, T.; Eisaku, T.; Yamagishi, Y. New Cyclic Peptide Compounds. WO 2007/049803, 2007.
130. Kobayashi, M.; Sasamura, S.; Muramatsu, H.; Tsurumi, Y.; Takase, S.; Okaka, K. New Cyclic Peptide Compounds. WO 2006/054801, 2006.
131. Yamanaka, T.; Ohki, H.; Ishida, J.; Toda, A.; Harayama, Y.; Makino, T.; Kunikawa, S.; Mizuno, H.; Ohtake, H. New Cyclic Peptide Compounds. WO 2008/139986, 2008.
132. Sedrani, R.; Kallen, J.; Martin Cabrejas, L. M.; Papageorgiou, C. D.; Senia, F.; Rohrbach, S.; Wagner, D.; Thai, B.; Jutzi Eme, A.-M.; France, J.; Oberer, L.; Rihs, G.; Zenke, G.; Wagner, J. Sanglifehrin-Cyclophilin Interaction: Degradation Work, Synthetic Macrocyclic Analogues, X-ray Crystal Structure, and Binding Data J. Am. Chem. Soc. 2003, 125, 3849-3859
133. Kallen, J.; Sedrani, R.; Zenke, G.; Wagner, J. Structure of Human Cyclophilin A in Complex with the Novel Immunosuppressant Sanglifehrin A at 1.6 Å Resolution J. Biol. Chem. 2005, 280, 21965-21971
134. Zenke, G.; Strittmatter, U.; Fuchs, S.; Quesniaux, V. F.; Brinkmann, V.; Schuler, W.; Zurini, M.; Enz, A.; Billich, A.; Sanglier, J. J.; Fehr, T. Sanglifehrin A, a Novel Cyclophilin-Binding Compound Showing Immunosuppressive Activity with a New Mechanism of Action J. Immunol. 2001, 166, 7165-7171
135. Härtel, C.; Iblher, P.; Puzik, A.; Wortmeier, K.; Ebel, B.; Schultz, C.; Müller-Steinhardt, M. Immunosuppressive Activity of the Immunophilin-Binding Drug Sanglifehrin A in Human Whole Blood: Potent Inhibition of Interleukin-6 Produced by Lymphocytes and Monocytes Scand. J. Immunol. 2006, 63, 26-34
136. Immecke, S. N.; Baal, N.; Wilhelm, J.; Bechtel, J.; Knoche, A.; Bein, G.; Hackstein, H. The Cyclophilin-Binding Agent Sanglifehrin A Is a Dendritic Cell Chemokine and Migration Inhibitor PLoS One 2011, 6, e18406
137. Gregory, M. A.; Bobardt, M.; Obeid, S.; Chatterji, U.; Coates, N. J.; Foster, T.; Gallay, P.; Leyssen, P.; Moss, S. J.; Neyts, J.; Nur-e-Alam, M.; Paeshuyse, J.; Piraee, M.; Suthar, D.; Warneck, T.; Zhang, M.-Q.; Wilkinson, B. Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin Family Antimicrob. Agents Chemother. 2011, 55, 1975-1981
138. Moss, S. J.; Bobardt, M.; Leyssen, P.; Coates, N.; Chatterji, U.; Dejian, X.; Foster, T.; Liu, J.; Nur-e-Alam, M.; Suthar, D.; Yongsheng, C.; Warneck, T.; Zhang, M.-Q.; Neyts, J.; Gallay, P.; Wilkinson, B.; Gregory, M. A. Sangamides, a New Class of Cyclophilin-Inhibiting Host-Targeted Antivirals for Treatment of HCV Infection MedChemComm 2012, 3, 944
139. Moss, S. J.; Gregory, M. A.; Wilkinson, B. Macrocyclic Compounds and Methods for Their Production. WO 2012/131377, 2012.
140. Moss, S. J.; Gregory, M. A.; Wilkinson, B. Macrocyclic Compound and Methods for Its Production. WO 2012/131371, 2012.
141. Aciro, C.; Steadman, V. A.; Pettit, S. N.; Poullennec, K. G.; Lazarides, L.; Dean, D. K.; Bar, N. A.; Highton, A. J.; Keats, A. J.; Siegel, D. S.; Karki, K. K.; Schrier, A. J.; Jansa, P.; Mackman, R. Macrocyclic Inhibitors of Flaviviridae Viruses. WO 2013/185103, 2013.
142. Steadman, V. A.; Poullennec, K. G.; Lazarides, L.; Aciro, C.; Dean, D. K.; Keats, A. J.; Siegel, D. S.; Schrier, A. J.; Mackman, R.; Jansa, P. Macrocyclic Inhibitors of Flaviviridae Viruses. WO 2013/185093, 2013.
143. Aciro, C.; Steadman, V. A.; Pettit, S. N.; Poullennec, K. G.; Lazarides, L.; Dean, D. K.; Bar, N. A.; Highton, A. J.; Keats, A. J.; Siegel, D. S.; Karki, K. K.; Schrier, A. J.; Jansa, P.; Mackman, R. Macrocyclic Inhibitors of Flavivirdae Viruses. WO 2013/185090, 2013.
144. Appleby, T.; Fliri, H. G.; Keats, A. J.; Lazarides, L.; Mackman, R.; Pettit, S. N.; Poullennec, K. G.; Sanvoisin, J.; Steadman, V. A.; Watt, G. M. Macrocyclic Inhibitors of Flaviviridae Viruses. WO 2012/078915, 2012.
145. Guichou, J.-F.; Colliandre, L.; Ahemed-Belkacem, H.; Pawlotsky, J.-M. New Inhibitors of Cyclophilins and Uses Thereof. WO 2011/076784, 2011.